Hyperoside mediates protection from diabetes kidney disease by regulating ROS‐ERK signaling pathway and pyroptosis
Phytotherapy Research · 2023-12 · 37 (12) · 5871-5882
DOI: 10.1002/ptr.7993 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 30.08.2023. Verfasst von Kejia Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Public Experimental Research Center, Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Training Program of Innovation and Entrepreneurship for Undergraduates.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Renal tubular injury is a key factor in the progression of diabetic kidney disease to end‐stage renal disease. Hyperoside, a natural flavonol glycoside in various plants, is a potentially effective drug for the clinical treatment of diabetic kidney disease. However, the specific mechanisms remain unknown. Therefore, this study will explore the effect and mechanism of hyperoside on renal tubulointerstitium in diabetic kidney disease. db/db mouse (C57BL/KsJ) is a model of type 2 diabetes resulting from Leptin receptor point mutations, with the appearance of diabetic kidney disease. Therefore, db/db mice were used for in vivo experimental studies. In vitro, human renal tubular epithelial cells were incubated with bovine serum albumin to simulate the injury of renal tubular epithelial cells caused by excessive albumin in primary urine. The experimental results showed that hyperoside could improve kidney function and reduce kidney tissue damage in mice, and could inhibit oxidative stress, extracellularly regulated protein kinases 1/2 signaling activation, and pyroptosis in human renal tubular epithelial cells. Therefore, hyperoside inhibited oxidative stress by regulating the activation of the extracellularly regulated protein kinases 1/2/mitogen‐activated protein kinase signaling pathway, thereby alleviating proteinuria‐induced pyroptosis in renal tubular epithelial cells. This study provides novel evidence that could facilitate the clinical application of hyperoside in diabetic kidney disease treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Public Experimental Research Center, Xuzhou Medical University, Xuzhou, China.
- Department of Pathophysiology, Xuzhou Medical University, Xuzhou, China.
- Laboratory of Clinical and Experimental Pathology, Xuzhou Medical University, Xuzhou, China.
- The Second Clinical Medical School, Xuzhou Medical University, Xuzhou, China.
- Department of Physiology, Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Kejia Zhang, Kaiwen Yin, Minjie Wang, Qiuchi Dong, Zilan Miao, Yubo Guan, Qi Wu, Yao Zhou
Förderung
- National Natural Science Foundation of China
- Jiangsu Training Program of Innovation and Entrepreneurship for Undergraduates
Zitieren
APA
Zhang, K., Li, M., Yin, K., Wang, M., Dong, Q., Miao, Z., Guan, Y., Wu, Q., & Zhou, Y. (2023). Hyperoside mediates protection from diabetes kidney disease by regulating ROS‐ERK signaling pathway and pyroptosis. Phytotherapy Research, 37(12), 5871-5882. https://doi.org/10.1002/ptr.7993
Vancouver
Zhang K, Li M, Yin K, Wang M, Dong Q, Miao Z, et al. Hyperoside mediates protection from diabetes kidney disease by regulating ROS‐ERK signaling pathway and pyroptosis. Phytotherapy Research. 2023;37(12):5871-5882. doi:10.1002/ptr.7993
BibTeX
@article{Zhang2023,
author = {Zhang, Kejia and Li, MiaoMiao and Yin, Kaiwen and Wang, Minjie and Dong, Qiuchi and Miao, Zilan and Guan, Yubo and Wu, Qi and Zhou, Yao},
title = {Hyperoside mediates protection from diabetes kidney disease by regulating ROS‐ERK signaling pathway and pyroptosis},
journal = {Phytotherapy Research},
year = {2023},
volume = {37},
number = {12},
pages = {5871--5882},
doi = {10.1002/ptr.7993}
}
EUVIMED